Aerosol Delivery Devices Market Value to grasp $46.72 million by 2027 | 3M Company, Aerogen, Inc.

According to the research report published by Allied Market Research, the global aerosol delivery devices market is expected to register a CAGR of 4.9% from 2020 to 2027. The research includes changing market dynamics, top impacting factors, key investment pockets, value chain, and competitive scenario. Through tabular and graphical representation, the report offers key insights on different aspects of the market such as current market size and estimations, region-wise analysis, and opportunities. Porter’s Five Forces analysis has been mentioned in the report to outline competitive intensity. The report is a helpful source of information to unlock potential from emerging countries and expand businesses to gain international presence.

Aerosol delivery devices are generally used as facilitators to provide drugs to patients. Inhaled medication through lungs is mostly provided to prevent or relieve asthma, COPD and other respiratory & non-respiratory ailments. Advantages of aerosol delivery devices are direct deposition of inhaled medication to airway receptor sites, rapid onset of action of broncho-active drugs, and relative ease & convenience of self-administration by patients. Common classes of drugs suitable for aerosol delivery include anticholinergic antagonists, beta agonists, and anti-inflammatory agents.

Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/7153

The aerosol delivery devices market is expected to experience significant growth during the forecast period, owing to rise in prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis; rise in need for rescue medication during sudden asthmatic attack; and rise in demand for short-term, effective aerosol drug delivery devices.

Moreover, increase in focus of manufacturers toward development of advanced, portable inhalation devices, surge in public awareness toward inhalation therapy, introduction of novel and advanced aerosol delivery devices in customized shapes and sizes, rise in geriatric population, and easy reimbursement policies associated with inhalation therapy are anticipated to drive growth of the aerosol delivery devices market. However, complications and side-effects associated with drug inhalation and high cost associated with nebulizers are expected to hinder growth of the aerosol delivery devices market. On the basis of product, the market is categorized into dry powder inhalers, metered dose inhalers, and nebulizers.

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. There are no drugs that are currently licensed for COVID-19 treatment or prevention. Increase in number of R&D activities and rise in use of aerosol delivery devices in clinical studies to develop medicines for treatment of COVID-19 is anticpated show positive impact on the market. For instance, Synairgen a UK-based respiratory drug discovery & Development Company launched home-based clinical trial of its inhaled IFN-β1a solution (SNG001) in patients with COVID-19.The dry powder inhalers (DPI) segment will show significant aerosol delivery devices market growth during the forecast period, owing to rise in demand for DPI, surge in patient awareness toward effective & advanced respiratory devices, advancements in DPI drug delivery, and launch of cost effective products.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/7153

On the basis of application, the market is segregated into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and non-respiratory diseases. Presently, the asthma segment accounts for majority of the aerosol delivery devices market share, owing to rise in prevalence of asthma in both developed as well as developing countries, surge in demand for metered dose inhalers (MDIs) to treat asthma, rise in smoking population, increase in air pollution, and surge in geriatric population facing chronic respiratory problems.

North America accounted for 41.16% of the global aerosol delivery devices market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to increase in number of asthma and COPD patients; higher healthcare awareness; early detection of respiratory diseases; availability of advanced healthcare facilities with trained medical professionals; rise in number of R&D activities, coupled with large presence of key players; and surge in investment made by governments in the healthcare system. However, Asia-Pacific is expected to experience highest growth during the forecast period, owing to improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, rise in healthcare reforms, and technological advancements in the field of healthcare.

Access Full Report @ https://www.alliedmarketresearch.com/aerosol-delivery-devices-market-A06788

Contact:

David Correa
Portland, OR, United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

This release was published on openPR.